Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. Chen Z, Vallega KA, Wang D, Bildtsen E, et al. Cancer Lett 2025;633:218010.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen Z, Vallega KA, Wang D, Bildtsen E, et al. Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. Cancer Lett 2025;633:218010.
PMID: 40886822